You searched for "ranibizumab"
An eye on novel anti-cancer agents: an evidence-based approach to external eye assessment
Novel anti-cancer therapies have led to significant advancement in cancer treatment, however, they can be associated with external eye complications. It is important to be mindful of such adverse effects during assessment of patients enrolled in clinical trials. Annually, approximately...SOS (Simplified Ophthalmic Statistics) Part 2: How to summarise your data and why it’s a good idea to do so
1 August 2018
| Catey Bunce
|
Ophthalmology
Studies involve capturing data. Statistical techniques allow data to be used to answer important research questions. A case series may have data on a handful of subjects but we are now entering the Big Data arena where datasets can be...
Brolucizumab in age-related macular degeneration, HAWK Study
3 October 2023
| Kurt Spiteri Cornish
|
Retina / Uvea / Vitreous
|
Neovascular age-related macular degeneration, aflibercept, anti-vascular endothelial growth factor therapy, brolucizumab, commercial formulation
The aim of the study was to collect additional data on efficacy and safety of brolucizumab 6mg intended for commercialization in age-related macular degeneration (AMD) (with an increase in pH and decrease in polysorbate concentration). The HAWK Study was a...
Addressing medical risk factors for diabetes and understanding the new systemic treatments
1 February 2014
| Samantha S Mann
As global diabetes figures continue to rise, the importance of reducing the burden of macrovascular and microvascular complications of diabetes has never been so great. By 2025 it is estimated that five million people in the UK will have diabetes...
More sensitive visual acuity test for age-related macular degeneration
1 October 2016
| Roger S Anderson (Prof), Nilpa Shah
|
EYE - Vitreo-Retinal
Age-related macular degeneration (AMD) is the leading cause of blindness in the developed world. Primarily associated with ageing, genetic factors and lifestyle choices such as smoking also play a contributory role. Patients with early AMD, characterised by the development of...
Real world data of post-IVT endophthalmitis, from a nurse-delivered intravitreal injection service
3 April 2023
| Yasir Khan, Robin Hamilton, Adam Mapani, Catey Bunce, Ranjan Rajendram, Carlos Pavesio
|
Ophthalmology
Introduction Intravitreal injection of neutralising anti-vascular endothelial growth factor (VEGF) antibody was licenced more than a decade ago, and over the years there has been proportionate increase in the number of intravitreal injections [1]. Injection of a therapeutic agent through...
Hot debates in medical retina and imaging: Perspectives from the Controversies in Ophthalmology 2020 virtual conference
Controversies in medical retina and imaging were debated during the Controversies in Ophthalmology 2020 virtual conference held during two mid-day scientific sessions on 27 and 28 March 2020. The author recounts key perspectives and presents viewpoint recommendations from the Vision...Short-term effects of intravitreal bevacizumab on the cornea
1 December 2014
| Khadijah Basheer
|
Cornea / External Eye Disease
|
anterior chamber depth, bevacizumab, central corneal thickness, intraocular pressure, iridocorneal angle, simulated keratometry
Bevacizumab has been extensively used to treat macula oedema and neovascularisation of the retina and it has also been useful in the management of corneal neovascular diseases. This prospective study aimed to provide more information on the effect bevacizumab may...
Sharing best practice and landmark evidence in glaucoma care
Evolving technology, best practice and landmark evidence in glaucoma care were reviewed by an international expert faculty in session presentations and debates during the 11th Moorfields International Glaucoma Symposium 2019. The authors were meeting chairs and provide an overview of...Intracameral bevacizumab as an adjunct to trabeculectomy
This is a 12-month, prospective, randomised, double-masked, placebo-controlled trial of patients who were not controlled medically with open angle glaucoma and scheduled for a primary trabeculectomy. Patients were recruited and randomised during the period between April 2009 and November 2010....High dose (2.5mg) bevacizumab for postradiation cystoid macular oedema
1 April 2017
| Yamini Krishna
|
Ocular Pathology and Oncology
|
Anti-VEGF, Cystoid macular edema, Melanoma, Radiation damage, Radiotherapy, Tumor
The authors present a retrospective, interventional case series investigating the efficacy of high dose (2.5mg/0.1ml) intravitreal bevacizumab in the treatment of persistent postradiation (Iodine-125 plaque brachytherapy for uveal melanoma) cystoid macular oedema (CME). Persistent CME was defined as increased or...